ArticleGeburtshilfe und Frauenheilkunde2025
Women with Gynecological Cancers Receiving Specialized Ambulatory Palliative Care (SAPV).
Article in Geburtshilfe und Frauenheilkunde, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A dignified final phase of life spent at home is what many people with terminal cancer wish for. There are currently no studies with large datasets on the palliative care of patients with gynecological tumors in the home environment. Material and Methods: Data from 5487 patients with gynecological-oncological disease who received specialized outpatient palliative care (SAPV) between 2017 and 2021 were included in the analysis. Results: The analysis showed that 88.8% of the patients died in a home environment and that their symptom burden remained stable or even decreased slightly during treatment. The median duration of active SAPV was 23 days. Factors such as age, comorbidities, and symptom burden at the start of treatment influenced the survival time of patients. The SAPV team and relatives who provided care in the home environment were mostly very satisfied with the care provided. Conclusion: The study provides important insights into the palliative care of patients with gynecological tumors and underscores the importance of SAPV for dignified end-of-life care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.